Accuracy of PREDICT+ to Determine OS in Early Breast Cancer
Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer.
Elisa Agostinetto, MD of the Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial (NCT00490139) of adjuvant lapatinib (Tykerb) with or without trastuzumab (Herceptin) versus trastuzumab alone in patients with HER2+ early breast cancer.
According to Agostinetto, PREDICT+ underestimated the survival of patients in the ALTTO trial. The 5-year overall survival (OS) prediction was 6.7 percentage points lower than what the actual 5-year OS was. These findings were consistent across all subgroups.
The greatest discrepancies were seen in patients with hormone receptor negative disease, node positive disease, and patients with larger tumor sizes. Discriminatory accuracy was also found to be low in the overall population. This finding was consistent across all subgroups.
T-DXd Shows Effectiveness in Treating HER2+ Advanced Solid Tumors
April 1st 2024The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.
Read More
Challenges Persist for HCPs and Patients With Breast Cancer
March 1st 2024In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.
Read More
